Needham analyst Gil Blum maintained a Buy rating on Artiva Biotherapeutics, Inc. today and set a price target of $18.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Gil Blum has given his Buy rating due to a combination of factors related to Artiva Biotherapeutics, Inc.’s recent developments and financial health. The company has reported promising early safety and translational data for its AlloNK program, which is a key driver for the stock. The initiation of dosing in a Phase IIa basket study for AlloNK in various autoimmune diseases beyond lupus, such as rheumatoid arthritis and Sjogren’s syndrome, indicates a broadening of their clinical research efforts.
Additionally, management’s optimism about the enrollment progress, with over 12 patients treated across multiple clinical sites, further supports the positive outlook. The updated results for AlloNK combined with Rituximab in aggressive non-Hodgkin lymphoma have shown encouraging durable responses, which are comparable to those seen with autologous CAR therapies. Furthermore, the company’s strong financial position, ending the second quarter of 2025 with approximately $142 million and maintaining cash runway guidance, adds to the confidence in its future prospects.
Blum covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Crispr Therapeutics AG, and Nurix Therapeutics. According to TipRanks, Blum has an average return of -3.1% and a 37.35% success rate on recommended stocks.